He Yu-B (02256.HK): The Phase II clinical study of the oral PD-L1 small molecule inhibitor ABSK043 combined with furmonertinib for the treatment of non-small cell lung cancer has completed the administration of the first patient.

Gelonghui Finance · Dec 10 18:03

Glory Holdings announced on December 11 that He Yu-B (02256.HK) has completed the administration of the first patient in a Phase II open-label clinical study (protocol number: ABSK043-202) evaluating the efficacy and safety of ABSK043 in combination with Furmonertinib for patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer. ABSK043 is an oral small molecule PD-L1 inhibitor independently developed by He Yu Pharmaceuticals, noted for its good bioavailability, high selectivity, and high activity, currently being developed for the treatment of various malignant tumors. Furmonertinib is a new Class 1 drug independently developed by Shanghai Allist Pharmaceuticals Co., Ltd., representing a new type of irreversible and selective EGFR-TKI targeted medication. The combination treatment of ABSK043 and Furmonertinib is expected to bring better clinical anti-tumor efficacy for patients with advanced lung cancer harboring EGFR mutations.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

和誉-B(02256.HK)：口服PD-L1小分子抑制剂ABSK043联合伏美替尼治疗非小细胞肺癌的II期临床研究完成首例患者给药

He Yu-B (02256.HK): The Phase II clinical study of the oral PD-L1 small molecule inhibitor ABSK043 combined with furmonertinib for the treatment of non-small cell lung cancer has completed the administration of the first patient.

Risk Disclaimer

Statement